PROCEPT BioRobotics Corporation Announces Aetna and Independence Blue Cross Blue Shield Positive Coverage Decisions Regarding Aquablation Therapy for Men with Enlarged Prostates
28 4월 2022 - 9:00PM
PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical
robotics company focused on advancing patient care by developing
transformative solutions in urology, today announced that Aetna US
Healthcare published an update to their Benign Prostatic
Hyperplasia (BPH) Clinical Policy Bulletin that provides a positive
coverage position expanding access to Aquablation therapy for the
treatment of their members with BPH. The revised policy is
effective April 26, 2022.
Aetna is the third largest national commercial insurer
in the United States with over 21 million covered lives
and one of the top five insurers in most states.
In addition, Independence Blue Cross Blue Shield, the leading
health insurance company in southeastern Pennsylvania, and a
licensee of the Blue Cross Blue Shield Association, updated its
policy for surgical treatments for BPH to include Aquablation
therapy as medically necessary when certain criteria are met.
Independence Blue Cross covers approximately 4 million covered
lives and the policy took effect April 25, 2022.
“We are pleased to see these large commercial plans recognize
the clinical outcomes of the recently published five-year data from
the WATER study,” said Reza Zadno, President and CEO. “We have made
considerable progress in the last 18 months, now having five of the
seven largest U.S. commercial payors establishing positive coverage
policies for Aquablation therapy to provide men suffering from BPH
a surgical treatment option that is clinically proven to
consistently remove prostate tissue independent of prostate size,
anatomy, or surgeon experience, with low risk of irreversible
outcomes.”
Aetna and Independence Blue Cross Blue Shield’s Updated Benign
Prostatic Hyperplasia coverage policy can be found here:
- https://www.aetna.com/cpb/medical/data/1_99/0079.html
-
https://medpolicy.ibx.com/ibc/Commercial/Pages/Policy/78855b23-e9d2-4cce-8573-9fdf4030a16f.aspx
About PROCEPT BioRobotics CorporationPROCEPT is
a surgical robotics company focused on advancing patient care by
developing transformative solutions in urology. PROCEPT develops,
manufactures and sells the AquaBeam Robotic System, an advanced,
image-guided, surgical robotic system for use in minimally invasive
urologic surgery with an initial focus on treating benign prostatic
hyperplasia, or BPH. BPH is the most common prostate disease and
impacts approximately 40 million men in the United States. PROCEPT
designed Aquablation therapy to deliver effective, safe and durable
outcomes for males suffering from lower urinary tract symptoms, or
LUTS, due to BPH that are independent of prostate size and shape or
surgeon experience. PROCEPT has developed a significant and growing
body of clinical evidence, which includes nine clinical studies and
over 100 peer-reviewed publications, supporting the benefits and
clinical advantages of Aquablation therapy.
Forward Looking StatementsThis release contains
forward‐looking statements within the meaning of federal securities
laws, including with respect to the Company’s projected financial
performance for full year 2022, statements regarding the potential
utilities, values, benefits and advantages of Aquablation® therapy
performed using PROCEPT’s products, including AquaBeam® Robotic
System, which involve risks and uncertainties that could cause the
actual results to differ materially from the anticipated results
and expectations expressed in these forward-looking statements. You
are cautioned not to place undue reliance on these forward-looking
statements. Forward-looking statements are only predictions based
on our current expectations, estimates, and assumptions, valid only
as of the date they are made, and subject to risks and
uncertainties, some of which we are not currently aware.
Forward-looking statements may include statements regarding
reimbursement coverage, market opportunity and penetration, the
Company’s possible or assumed future results of operations,
commercial momentum, or overall business strategy, Forward‐looking
statements should not be read as a guarantee of future performance
or results and may not necessarily be accurate indications of the
times at, or by, which such performance or results will be
achieved. These forward‐looking statements are based on PROCEPT’s
current expectations and inherently involve significant risks and
uncertainties. Actual results and the timing of events could differ
materially from those anticipated in such forward‐looking
statements as a result of these risks and uncertainties. These
risks and uncertainties are described more fully in the section
titled “Risk Factors” in PROCEPT’s filings with the Securities and
Exchange Commission (the “SEC”), including PROCEPT’s annual report
on From 10-K filed with the SEC on March 22, 2022. PROCEPT does not
undertake any obligation to update forward‐looking statements and
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward‐looking statements
contained herein. These forward-looking statements should not be
relied upon as representing PROCEPT’s views as of any date
subsequent to the date of this press release.
Important Safety
Information
All surgical treatments have inherent and associated side
effects. Please visit https://aquablation.com/safety-information/
for the potential side effects of Aquablation therapy.
Investor Contact:Gilmartin GroupMatt Bacso,
CFAMatt.bacso@gilmartinir.com
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024